U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

In a statement today, the company said it supports recent precautionary measures and that thorough investigations are needed ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC) ...

Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Read what ...

(RTTNews) - Valneva SE (VALN) announced the FDA and the U.S. Centers for Disease Control and Prevention have recommended a pause in the use of Valneva's single-dose live attenuated chikungunya ...

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...